GLOBAL HEALTH - RESEARCH AND DEVELOPMENT PARTNERSHIPS

Early day motion 439, tabled 29 October 2014 by Mark Durkan (Social Democratic and Labour Party). Signed by 21 members.

That this House pays tribute to the highly valuable and effective research and development (R&D) work into innovative global health goods carried out by public-private partnerships such as the European and Developing Countries Clinical Trials Partnership, the International AIDS Vaccine Alliance and the TB Alliance; highlights the important work these partnerships have done to accelerate the development of new or improved treatments, vaccines, microbicides, formulations and diagnostics against HIV/AIDS, tuberculosis and malaria with a focus on efficacy and implementation in affected regions such as sub-Saharan Africa; recognises that this work meets an urgent demand not currently met by market-based models of medical R&D and allows the integration and co-ordination of international research and the development of long-term medical research capacity in developing countries; and calls on the Government to maintain and employ its position as a leading funder of such partnerships to encourage increased contributions from other donor countries and private sector partners, particularly European Union member states.

Signatures by party: Labour 11, Liberal Democrat 3, Social Democratic and Labour Party 3, Alliance 1, DUP 1, Independent 1, Scottish National Party 1.